Ensuring compliance: A review of EU regulations and standards for incorporating legume and legume by-product proteins in food formulations.

Heliyon

School of Food Science and Environmental Health and Sustainability and Health Research Hub (SHRH), Technological University Dublin, Grangegorman, Dublin 7, D07 H6K8 89, Ireland.

Published: November 2024

Consumers are increasingly seeking nutritionally enhanced products, unique flavours and packaging, and ethically sourced ingredients. Significant technological advancements and investments in product innovation by manufacturers are driving the overall market growth for plant-based protein alternatives. In Europe, this growth is largely due to the rising adoption of veganism and the flexitarian trend. During vegetable processing, certain activities generate large amounts of by-products, many of which are discarded by manufacturers. These legumes and their by-products contain substantial amounts of protein. Manufacturers using legumes and their by-products-based proteins in food formulations must comply with European Union (EU) regulations and standards to obtain market approval. For this study, the regulatory framework and novel food dossier application process were sourced from the official EU website (Europa), while relevant standards were obtained from the International Organisation for Standardisation (ISO) and European Committee for Standardisation (CEN)-European Committee for Electrotechnical Standardisation (CENELEC) website. This review provides an overview of protein extraction from legumes and their by-products, followed by an analysis of the legal requirements for processing, production, and commercialisation of these extracted proteins in food formulations. It addresses standardisation and relevant standards in areas such as characterisation and safety. Furthermore, the novel food dossier application process and the EU requirements for legume proteins, if considered novel in the EU, are discussed. This review aims to serve as a guide for manufacturers already using, or considering the use of, legume proteins in food formulations within the EU, providing essential insights for gaining market acceptance and regulatory approval for these ingredients, whether existing or novel. Further research is needed to explore the incorporation of proteins extracted from legume by-products into food formulations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550120PMC
http://dx.doi.org/10.1016/j.heliyon.2024.e39821DOI Listing

Publication Analysis

Top Keywords

food formulations
20
proteins food
16
regulations standards
8
manufacturers legumes
8
legumes by-products
8
novel food
8
food dossier
8
dossier application
8
application process
8
relevant standards
8

Similar Publications

Current State of Research on Health-Promoting Functional Properties in Berry-Based Foods.

Curr Nutr Rep

January 2025

Departamento de Industrias, Facultad de Ciencias Exactas y Naturales, ITAPROQ (UBA-CONICET), Universidad de Buenos Aires, Intendente Güiraldes, s/n, Ciudad Universitaria, Buenos Aires, 1428, Argentina.

Purpose Of Review: This review aims to consolidate recent findings on the development and functional validation of berry-based foods while proposing guidelines for future advancements.

Recent Findings: Current investigations on berry-based functional foods (dairy and bakery products, snacks, etc.) emphasize their potential health benefits, including antioxidant effects, glycemic control, enzyme modulation, among others.

View Article and Find Full Text PDF

(L.) DC., commonly known as Japanese pepper, is a deciduous shrub native to East Asia.

View Article and Find Full Text PDF

Phosphodiesterase-4 (PDE4) is involved in the synthesis of inflammatory cytokines that mediate several chronic inflammatory disorders, including psoriasis and atopic dermatitis. In recent years, the therapeutic armamentarium in dermatology has expanded with the introduction of PDE4 inhibitors, both in oral and topical formulations. PDE4 inhibitors have gained increasing interest due to their remarkable safety record and ease of prescription, as evidenced by the recent influx of literature detailing its off-label uses.

View Article and Find Full Text PDF

This study explores the development and characterization of lyophilized chondroitin sulfate (CHON)-loaded solid lipid nanoparticles (SLN) as an innovative platform for advanced drug delivery. Solid lipid nanoparticles are increasingly recognized for their biocompatibility, their ability to encapsulate diverse compounds, their capacity to enhance drug stability, their bioavailability, and their therapeutic efficacy. CHON, a naturally occurring glycosaminoglycan with anti-inflammatory and regenerative properties, was integrated into SLN formulations using the hot microemulsion technique.

View Article and Find Full Text PDF

3D-Printed Tablets of Nifurtimox: In Vitro and In Vivo Anti- Studies.

Pharmaceutics

January 2025

Institute of Chemistry Rosario, National Council for Scientific and Technical Research (IQUIR-CONICET), Rosario 2000, Argentina.

: Chagas disease is a neglected tropical disease caused by infection with the parasite . Benznidazole and nifurtimox are the only approved drugs for treating this condition, but their low aqueous solubility may lead to erratic bioavailability. This work aimed for the first time to formulate tablets of nifurtimox by hot melt extrusion coupled with 3D printing as a strategy to increase drug dissolution and the production of tablets with dosage on demand.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!